Our study indicates that the development of miR-4454 as a microRNA-based therapeutic approach for silencing GNL3L may remarkably reduce oncogenic cell survival that depends on GNL3L/NF-κB signaling, making miR-4454 a candidate modality for treating metastatic human CRC. This evidence concerns the gene GNL3L and colorectal carcinoma.